467 related articles for article (PubMed ID: 32684497)
1. Vaccines based on virus-like nano-particles for use against Middle East Respiratory Syndrome (MERS) coronavirus.
Hashemzadeh A; Avan A; Ferns GA; Khazaei M
Vaccine; 2020 Aug; 38(36):5742-5746. PubMed ID: 32684497
[TBL] [Abstract][Full Text] [Related]
2. Vaccine Candidates against Coronavirus Infections. Where Does COVID-19 Stand?
Al-Kassmy J; Pedersen J; Kobinger G
Viruses; 2020 Aug; 12(8):. PubMed ID: 32784685
[TBL] [Abstract][Full Text] [Related]
3. Immune Responses to SARS-CoV, MERS-CoV and SARS-CoV-2.
İnandıklıoğlu N; Akkoc T
Adv Exp Med Biol; 2020; 1288():5-12. PubMed ID: 32514817
[TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2: previous coronaviruses, immune response, and development of vaccines.
De León-Rodríguez SG; Hernández-Rico B; Olmo-Vázquez GD; Cruz-Dávalos I; Bonifaz LC
Bol Med Hosp Infant Mex; 2020; 77(5):252-261. PubMed ID: 33064679
[TBL] [Abstract][Full Text] [Related]
5. Vaccination strategies to combat novel corona virus SARS-CoV-2.
Pandey SC; Pande V; Sati D; Upreti S; Samant M
Life Sci; 2020 Sep; 256():117956. PubMed ID: 32535078
[TBL] [Abstract][Full Text] [Related]
6. [Strategies for vaccine development of COVID-19].
Yang L; Tian D; Liu W
Sheng Wu Gong Cheng Xue Bao; 2020 Apr; 36(4):593-604. PubMed ID: 32347054
[TBL] [Abstract][Full Text] [Related]
7. Development of virus-like particles-based vaccines against coronaviruses.
Yong CY; Liew WPP; Ong HK; Poh CL
Biotechnol Prog; 2022 Nov; 38(6):e3292. PubMed ID: 35932092
[TBL] [Abstract][Full Text] [Related]
8. [Diagnosis, treatment, control and prevention of SARS-CoV-2 and coronavirus disease 2019: back to the future].
Ye ZW; Jin DY
Sheng Wu Gong Cheng Xue Bao; 2020 Apr; 36(4):571-592. PubMed ID: 32347053
[TBL] [Abstract][Full Text] [Related]
9. Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development.
Kim E; Erdos G; Huang S; Kenniston TW; Balmert SC; Carey CD; Raj VS; Epperly MW; Klimstra WB; Haagmans BL; Korkmaz E; Falo LD; Gambotto A
EBioMedicine; 2020 May; 55():102743. PubMed ID: 32249203
[TBL] [Abstract][Full Text] [Related]
10. Lessons for COVID-19 Immunity from Other Coronavirus Infections.
Sariol A; Perlman S
Immunity; 2020 Aug; 53(2):248-263. PubMed ID: 32717182
[TBL] [Abstract][Full Text] [Related]
11. Perspectives on development of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Zhang C; Zhou C; Shi L; Liu G
Hum Vaccin Immunother; 2020 Oct; 16(10):2366-2369. PubMed ID: 32961082
[TBL] [Abstract][Full Text] [Related]
12. Coronavirus Disease 2019: Coronaviruses and Blood Safety.
Chang L; Yan Y; Wang L
Transfus Med Rev; 2020 Apr; 34(2):75-80. PubMed ID: 32107119
[TBL] [Abstract][Full Text] [Related]
13. Preparation of virus-like particle mimetic nanovesicles displaying the S protein of Middle East respiratory syndrome coronavirus using insect cells.
Kato T; Takami Y; Kumar Deo V; Park EY
J Biotechnol; 2019 Dec; 306():177-184. PubMed ID: 31614169
[TBL] [Abstract][Full Text] [Related]
14. The novel zoonotic COVID-19 pandemic: An expected global health concern.
Contini C; Di Nuzzo M; Barp N; Bonazza A; De Giorgio R; Tognon M; Rubino S
J Infect Dev Ctries; 2020 Mar; 14(3):254-264. PubMed ID: 32235085
[TBL] [Abstract][Full Text] [Related]
15. MERS-CoV virus-like particles produced in insect cells induce specific humoural and cellular imminity in rhesus macaques.
Wang C; Zheng X; Gai W; Zhao Y; Wang H; Wang H; Feng N; Chi H; Qiu B; Li N; Wang T; Gao Y; Yang S; Xia X
Oncotarget; 2017 Feb; 8(8):12686-12694. PubMed ID: 27050368
[TBL] [Abstract][Full Text] [Related]
16. Development of epitope-based peptide vaccine against novel coronavirus 2019 (SARS-COV-2): Immunoinformatics approach.
Bhattacharya M; Sharma AR; Patra P; Ghosh P; Sharma G; Patra BC; Lee SS; Chakraborty C
J Med Virol; 2020 Jun; 92(6):618-631. PubMed ID: 32108359
[TBL] [Abstract][Full Text] [Related]
17. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.
Lambert PH; Ambrosino DM; Andersen SR; Baric RS; Black SB; Chen RT; Dekker CL; Didierlaurent AM; Graham BS; Martin SD; Molrine DC; Perlman S; Picard-Fraser PA; Pollard AJ; Qin C; Subbarao K; Cramer JP
Vaccine; 2020 Jun; 38(31):4783-4791. PubMed ID: 32507409
[TBL] [Abstract][Full Text] [Related]
18. MERS-CoV spike nanoparticles protect mice from MERS-CoV infection.
Coleman CM; Venkataraman T; Liu YV; Glenn GM; Smith GE; Flyer DC; Frieman MB
Vaccine; 2017 Mar; 35(12):1586-1589. PubMed ID: 28237499
[TBL] [Abstract][Full Text] [Related]
19. Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2.
Zhang XY; Huang HJ; Zhuang DL; Nasser MI; Yang MH; Zhu P; Zhao MY
Infect Dis Poverty; 2020 Jul; 9(1):99. PubMed ID: 32690096
[TBL] [Abstract][Full Text] [Related]
20. Evaluating the potential impact of targeted vaccination strategies against severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) outbreaks in the healthcare setting.
Abdirizak F; Lewis R; Chowell G
Theor Biol Med Model; 2019 Oct; 16(1):16. PubMed ID: 31587665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
